<DOC>
	<DOCNO>NCT02728089</DOCNO>
	<brief_summary>This Phase 3 , multi-site , non-randomized , open-label study evaluate safety efficacy MK-7625A 1.5 g ( ceftolozane 1 g/tazobactam 0.5 g ) treatment complicate urinary tract infection ( cUTI ) include pyelonephritis ( uncomplicated complicate pyelonephritis complicate low urinary tract infection ) Japanese participant . Efficacy primarily assess microbiological response define eradication baseline pathogen pathogen .</brief_summary>
	<brief_title>Study Ceftolozane/Tazobactam ( MK-7625A ) Japanese Participants With Uncomplicated Pyelonephritis Complicated Urinary Tract Infection ( MK-7625A-014 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<criteria>Japanese male female need hospitalization Clinical sign and/or symptom urinary tract infection ( UTI ) screen visit , either one following : Pyelonephritis ( uncomplicated complicate ) Complicated low UTI ( cUTI ) Has pretreatment baseline urine culture specimen obtain within 24 hour start study drug Requires IV antibacterial therapy treatment presume UTI Female participant child bear potential must pregnant ( negative human chorionic gonadotropin test ) breastfeeding must agree use adequate contraception duration study 35 day last dose study drug Male participant must agree use adequate contraception duration study 75 day last dose study drug Has history recent recurrent Grampositive organism UTI suggest colonization , participant UTI show suspect presence Grampositive organism Has history moderate severe hypersensitivity allergic reaction Betalactam antibacterial include cephalosporin , carbapenems penicillin , tazobactam Has concomitant infection time randomization , require nonstudy systemic antibacterial therapy addition study drug exception antibacterial Grampositive activity ( vancomycin , linezolid , daptomycin teicoplanin ) Is receive probenecid Is currently receive bladder infusion topical urinary antiseptic antibacterial agent Has receive amount potentially therapeutic antibacterial therapy collection pretreatment baseline urine culture administration first dose study drug . Has receive dose potentially therapeutic antibacterial agent treatment current UTI within 48 hour pretreatment baseline urine obtain Intractable urinary infection baseline would require 7 day study drug Has complete , permanent obstruction urinary tract . Has confirm fungal urinary tract infection time randomization ( ≥ 10^3 fungal colony form unit /mL ) Has permanent indwell bladder catheter urinary stent include nephrostomy Has suspect confirm perinephric intrarenal abscess Has suspect confirm prostatitis , urethritis , epididymitis Has ileal loop know vesicoureteral reflux Severe impairment renal function include estimate CrCl &lt; 30 mL/min , requirement peritoneal dialysis , hemodialysis hemofiltration , oliguria ( &lt; 20 mL/h urine output 24 hour ) Has urinary catheter schedule removed end therapy Has rapidly progress disease immediately lifethreatening illness include acute hepatic failure , respiratory failure , septic shock Has immunocompromising condition ( i.e. , AIDS , hematological malignancy , bone marrow transplantation , immunosuppressive therapy ) receive ≥ 40 mg prednisone per day administer continuously &gt; 14 day prior study start Has participate clinical study investigational product within 30 day prior first dose study drug Has previously participate study ceftolozane MK7625A .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>